One-Pot, Mix-and-Read Peptide-MHC Tetramers
Open Access
- 27 February 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (2) , e1678
- https://doi.org/10.1371/journal.pone.0001678
Abstract
Cytotoxic T Lymphocytes (CTL) recognize complexes of peptide ligands and Major Histocompatibility Complex (MHC) class I molecules presented at the surface of Antigen Presenting Cells (APC). Detection and isolation of CTL's are of importance for research on CTL immunity, and development of vaccines and adoptive immune therapy. Peptide-MHC tetramers have become important reagents for detection and enumeration of specific CTL's. Conventional peptide-MHC-tetramer production involves recombinant MHC production, in vitro refolding, biotinylation and tetramerization; each step followed by various biochemical steps such as chromatographic purification, concentration etc. Such cumbersome production protocols have limited dissemination and restricted availability of peptide-MHC tetramers effectively precluding large-scale screening strategies involving many different peptide-MHC tetramers. We have developed an approach whereby any given tetramer specificity can be produced within 2 days with very limited effort and hands-on time. The strategy is based on the isolation of correctly oxidized, in vivo biotinylated recombinant MHC I heavy chain (HC). Such biotinylated MHC I HC molecules can be refolded in vitro, tetramerized with streptavidin, and used for specific T cell staining-all in a one-pot reaction without any intervening purification steps. We have developed an efficient “one-pot, mix-and-read” strategy for peptide-MHC tetramer generation, and demonstrated specific T cell straining comparable to a commercially available MHC-tetramer. Here, seven peptide-MHC tetramers representing four different human MHC (HLA) class I proteins have been generated. The technique should be readily extendable to any binding peptide and pre-biotinylated MHC (at this time we have over 40 different pre-biotinylated HLA proteins). It is simple, robust, and versatile technique with a very broad application potential as it can be adapted both to small- and large-scale production of one or many different peptide-MHC tetramers for T cell isolation, or epitope screening.Keywords
This publication has 18 references indexed in Scilit:
- Expansion of CD8+ Cytotoxic T Cells in vitro and in vivo Using MHC Class I TetramersTumor Biology, 2007
- Generation of peptide–MHC class I complexes through UV-mediated ligand exchangeNature Protocols, 2006
- A reproducible method for the enumeration of functional (cytokine producing)versusnon-functional peptide-specific cytotoxic T lymphocytes in human peripheral bloodClinical and Experimental Immunology, 2006
- In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramersHuman Immunology, 2004
- Purification of correctly oxidized MHC class I heavy‐chain molecules under denaturing conditions: A novel strategy exploiting disulfide assisted protein foldingProtein Science, 2003
- Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexesBritish Journal of Cancer, 2002
- Establishment of a quantitative ELISA capable of determining peptide – MHC class I interactionTissue Antigens, 2002
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Idiotype‐specific T cells in multiple myeloma stage I: an evaluation by four different functional testsBritish Journal of Haematology, 1995
- A novel two colour ELISPOT assayJournal of Immunological Methods, 1988